A decent start to 2024; guidance unchanged
30/04/24 -"Qiagen started 2024 on a decent note with the operating performance in line with the street’s expectations but above the management’s guidance. As the 2024 sales guidance remained unchanged, a ..."
Pages
64
Language
English
Published on
30/04/24
You may also be interested by these reports :
17/05/24
Clariane communicated more details regarding its projected capital increases and the entry of a new anchor shareholder in its capital. We take this ...
17/05/24
We have incorporated the detailed information provided by Clariane regarding its projected capital increases. This has resulted in only minor changes ...
16/05/24
On the back of the promising beginning to 2024, which was a combination of 1/ normalising market demand in Europe (the lynchpin geography); 2/ the ...
16/05/24
As we have consistently argued over the last 3 years, Health stocks (ex Pharma) are long on growth promises and short on delivery. The gap stems from ...